Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection
Nifuroxazide and vancomycin have demonstrated accelerated improvement in patient status and hold promise as a novel dual therapeutic regimen for managing patients diagnosed with a medium-severe form of CDI.
Authors
- Marijana Marković Boras (ORCID: https://orcid.org/0000-0002-5575-8893)
- Amina Džidić-Krivić
- Esma Karahmet Farhat
- Ervin Alibegović
- Lana Lekić (ORCID: https://orcid.org/0000-0001-7862-7100)
- Emina Karahmet Sher
- Jasna Rahimić
Institutions
- University of Sarajevo (BA)
- University of Tuzla (BA)
- University of Zenica (BA)
- University Clinical Hospital Mostar (BA)
- University of Osijek (HR)
- Nottingham Trent University (GB)
Publication Details
- Journal
- Antibiotics
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3390/antibiotics14040400
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- NIH Clinical Center